Clinical trials · New York, NY
Friedreich Ataxia clinical trials in New York
We’re tracking 4 recruiting friedreich ataxia studies with a site in or near New York — including Phase 1, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near New York
- NCT02316314Recruiting
Study heart scan and function in people with Friedreich’s ataxia
This study uses heart tests (including ultrasound and MRI) to better understand how Friedreich’s ataxia affects the heart. You might benefit by getting detailed heart evaluation and contributing to research that could guide future care.
New York, New YorkAges 12–50 - NCT05302271RecruitingPhase 1
Testing gene therapy for Friedreich’s ataxia heart disease
This Phase 1 trial tests an AAV gene therapy that aims to improve heart problems caused by Friedreich’s ataxia. You may be eligible if you have genetically confirmed Friedreich’s ataxia with measurable heart weakening but still enough heart function to safely receive treatment.
New York, New YorkAges 12–50 - NCT07778836RecruitingPhase 3
Study of daily injections for Friedreich's ataxia
This study tests an investigational drug given as a daily injection to see if it can improve walking and balance in people with Friedreich's ataxia.
Eatontown, New JerseyAges 12–40 - NCT06447025RecruitingPhase 2
Study of CTI-1601 for people with Friedreich's ataxia
This trial tests an injectable medicine called CTI-1601 for Friedreich's ataxia (FRDA). It is an open-label study, meaning everyone knows they are getting the drug. The study is for people who have taken CTI-1601 before (without serious side effects) or are new to the drug.
Eatontown, New JerseyAges 2–60
Hear when a new Friedreich Ataxia trial opens near New York, NY
We’ll email you when one opens near New York, NY — at most once a week, no account needed, unsubscribe anytime.
Friedreich Ataxia trials in other cities
Where these studies are running near New York
Institutions with a site for the recruiting friedreich ataxia studies listed above.
- Clinilabs Drug Development Corporation · 2 studies
- Weill Cornell Medicine · 2 studies
What taking part in a friedreich ataxia study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Common questions
- Are there friedreich ataxia clinical trials near New York?
- Yes. We're currently tracking 4 recruiting friedreich ataxia studies with a site near New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a friedreich ataxia study near New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site near New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a friedreich ataxia trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New friedreich ataxia studies open near New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.